Journal: Pharmaceutics

Article Title: Synergistic Encapsulation of Paclitaxel and Sorafenib by Methoxy Poly(Ethylene Glycol)- b -Poly(Caprolactone) Polymeric Micelles for Ovarian Cancer Therapy

doi: 10.3390/pharmaceutics15041206

Figure Lengend Snippet: IC 50 and CI values of paclitaxel (PTX) and sorafenib (SRF) at various molar ratios (n = 3).

Article Snippet: SKOV3-red-fluc, a cancer cell line in which a fluorescent factor was introduced into SKOV3, a human OC cell line, was purchased from PerkinElmer (Waltham, MA, USA).

Techniques:

Journal: Pharmaceutics

Article Title: Synergistic Encapsulation of Paclitaxel and Sorafenib by Methoxy Poly(Ethylene Glycol)- b -Poly(Caprolactone) Polymeric Micelles for Ovarian Cancer Therapy

doi: 10.3390/pharmaceutics15041206

Figure Lengend Snippet: In vitro cytotoxicity analysis of SKOV3-red-fluc ( A ) PTX solution, ( B ) PTX micelle, ( C ) SRF solution, ( D ) SRF micelle, ( E ) PTX/SRF solution, and ( F ) PTX/SRF micelle (n = 6).

Article Snippet: SKOV3-red-fluc, a cancer cell line in which a fluorescent factor was introduced into SKOV3, a human OC cell line, was purchased from PerkinElmer (Waltham, MA, USA).

Techniques: In Vitro

Journal: Pharmaceutics

Article Title: Synergistic Encapsulation of Paclitaxel and Sorafenib by Methoxy Poly(Ethylene Glycol)- b -Poly(Caprolactone) Polymeric Micelles for Ovarian Cancer Therapy

doi: 10.3390/pharmaceutics15041206

Figure Lengend Snippet: Colony formation inhibition in SKOV3-red-fluc cell line solution and micelles ( A ) free PTX, ( B ) PTX micelle, ( C ) free SRF, ( D ) SRF micelle, ( E ) free PTX/SRF, and ( F ) PTX/SRF micelle (n = 3).

Article Snippet: SKOV3-red-fluc, a cancer cell line in which a fluorescent factor was introduced into SKOV3, a human OC cell line, was purchased from PerkinElmer (Waltham, MA, USA).

Techniques: Inhibition

Journal: Pharmaceutics

Article Title: Synergistic Encapsulation of Paclitaxel and Sorafenib by Methoxy Poly(Ethylene Glycol)- b -Poly(Caprolactone) Polymeric Micelles for Ovarian Cancer Therapy

doi: 10.3390/pharmaceutics15041206

Figure Lengend Snippet: ( A ) Morphological observation of tumor spheroids prepared with SKOV3-red-fluc, ( B ) Control, PTX Solution, PTX micelles, PTX/SRF Solution, and PTX/SRF micelles SKOV3-red-fluc tumor spheroid IVIS measured with D-luciferin before treatment and after secondary treatment image (n = 4). ( C ) A graph showing the total luminescence value reflecting the tumor size for the first and second drug treatments based on the tumor spheroid before drug treatment (** p < 0.01, n = 4).

Article Snippet: SKOV3-red-fluc, a cancer cell line in which a fluorescent factor was introduced into SKOV3, a human OC cell line, was purchased from PerkinElmer (Waltham, MA, USA).

Techniques: Control

Journal: Pharmaceutics

Article Title: Synergistic Encapsulation of Paclitaxel and Sorafenib by Methoxy Poly(Ethylene Glycol)- b -Poly(Caprolactone) Polymeric Micelles for Ovarian Cancer Therapy

doi: 10.3390/pharmaceutics15041206

Figure Lengend Snippet: ( A ) Representative IVIS images of an SKOV3-red-fluc cell xenograft model taken 20 days after IV injection with DPBS (control), solution, and micelle, ( B ) relative total flux (% of day 9) value graph of each group (* p < 0.05, n = 5), ( C ) body weight change, ( D ) representative H&E staining of xenograft mouse model.

Article Snippet: SKOV3-red-fluc, a cancer cell line in which a fluorescent factor was introduced into SKOV3, a human OC cell line, was purchased from PerkinElmer (Waltham, MA, USA).

Techniques: IV Injection, Control, Staining

Journal: Journal of Gynecologic Oncology

Article Title: The relationship between cisplatin resistance and histone deacetylase isoform overexpression in epithelial ovarian cancer cell lines

doi: 10.3802/jgo.2012.23.3.182

Figure Lengend Snippet: A comparison of cisplatin resistance in SKOV3 and OVCAR3 cells treated with 15 µg/mL cisplatin. The number of viable cells was measured by CCK-8 assay. * p<0.05.

Article Snippet: The SKOV-3 and OVCAR3 human epithelial ovarian cancer cell lines were obtained from the Korean Cell Line Bank (Seoul, Korea).

Techniques: Comparison, CCK-8 Assay

Journal: Journal of Gynecologic Oncology

Article Title: The relationship between cisplatin resistance and histone deacetylase isoform overexpression in epithelial ovarian cancer cell lines

doi: 10.3802/jgo.2012.23.3.182

Figure Lengend Snippet: Protein expression levels of histone deacetylase (HDAC) isoforms in SKOV3 and OVCAR3 cells transfected with HDAC isoform expression vectors or not transfected as a control. Expression of β-actin was used as a loading control. endo, endogenous HDAC 1; exo, exogenous HDAC 1 which was transfected.

Article Snippet: The SKOV-3 and OVCAR3 human epithelial ovarian cancer cell lines were obtained from the Korean Cell Line Bank (Seoul, Korea).

Techniques: Expressing, Histone Deacetylase Assay, Transfection, Control

Journal: Journal of Gynecologic Oncology

Article Title: The relationship between cisplatin resistance and histone deacetylase isoform overexpression in epithelial ovarian cancer cell lines

doi: 10.3802/jgo.2012.23.3.182

Figure Lengend Snippet: Effect of overexpressed histone deacetylase (HDAC) isoforms on cisplatin resistance in OVCAR3 cells. OVCAR3 cells transfected with a unique HDAC isoform and nontransfected control cells were treated with 15 µg/mL cisplatin for 24 hours. Cell survival rate was measured by cell counting kit-8 (CCK-8) assay. The values were normalized to time 0 as a starting point and the survival rate was calculated by dividing the average number of treated cells by the average number of untreated cells. Each data set represents a relative percentage of nontransfected control values. Values are presented as mean±SE for three independent experiments. * p<0.05 compared with control.

Article Snippet: The SKOV-3 and OVCAR3 human epithelial ovarian cancer cell lines were obtained from the Korean Cell Line Bank (Seoul, Korea).

Techniques: Histone Deacetylase Assay, Transfection, Control, Cell Counting, CCK-8 Assay

Journal: Frontiers in Chemistry

Article Title: Lotus seed (Nelumbinis semen) extract: anticancer potential and chemoprofiling by in vitro , in silico and GC-MS studies

doi: 10.3389/fchem.2024.1505272

Figure Lengend Snippet: Annexin-V FITC/PI staining of apoptosis at 24 h of incubation. (A) SKOV3-CisR control, (B) A2780-CisR cells, (C) A2780-CisR control, (D) MELS treated SKOV3-CisR cells.

Article Snippet: Two human ovarian cancer cell lines, namely, SKOV3 and A2780, were obtained from the National Centre for Cell Sciences (NCCS), Pune, India.

Techniques: Staining, Incubation, Control

Journal: Frontiers in Chemistry

Article Title: Lotus seed (Nelumbinis semen) extract: anticancer potential and chemoprofiling by in vitro , in silico and GC-MS studies

doi: 10.3389/fchem.2024.1505272

Figure Lengend Snippet: Flow cytometric cell cycle distribution analysis. (A) SKOV3-CisR control cells, (B) MELS treated SKOV3-CisR, (C) Control cells of A2780-CisR, (D) MELS treated A2780-CisR cells.

Article Snippet: Two human ovarian cancer cell lines, namely, SKOV3 and A2780, were obtained from the National Centre for Cell Sciences (NCCS), Pune, India.

Techniques: Control

Journal: Frontiers in Pharmacology

Article Title: A Systematic Review of the Preventive and Therapeutic Effects of Naringin Against Human Malignancies

doi: 10.3389/fphar.2021.639840

Figure Lengend Snippet: Potential anticancer effects and related mechanisms of action of naringin based on in vitro studies.

Article Snippet: Ovarian , SKOV3/CDDP cell line , 10–40 μmol/L , Shandong Qilu Pharmaceutical Co., Ltd. (Shandong, China) , ND , Y , 48 h , ↓NF-κB, ↓COX-2 , .

Techniques: In Vitro, Control, Activity Assay, Inhibition, Protein-Protein interactions, Transduction, Purification, Mass Spectrometry, Migration, High Performance Liquid Chromatography

Journal: Oxidative Medicine and Cellular Longevity

Article Title: HSP90AB1 as the Druggable Target of Maggot Extract Reverses Cisplatin Resistance in Ovarian Cancer

doi: 10.1155/2023/9335440

Figure Lengend Snippet: ME enhances the sensitivity of A2780/CDDP and SKOV3/CDDP cells to cisplatin (Cis). Cells were treated with different concentrations of cisplatin with and without ME (6 mg/ml) for 48 h. (a) The viability of A2780 and A2780/CDDP cells was assayed using CCK8 kits. (b) The viability of SKOV3 and SKOV3/CDDP cells was assayed. SKOV3/CDDP cells were infected with lentiviral particles to express luciferase, and then cells were treated with cisplatin (3.2 μ g/ml) and/or ME (4 mg/ml or 6 mg/ml) for 48 h followed by 150 μ g/ml D-luciferin for 10 min. (c) The luciferase-positive SKOV3/CDDP cells were analyzed using Living Image software and a GloMax® 96 Microplate Luminometer. The quantification of luciferase-positive cells is shown on the right. ∗ p ≤ 0.05 vs. blank; # p ≤ 0.05 vs. cisplatin; (d) A2780/CDDP and SKOV3/CDDP cells were double stained with Annexin V-FITC and PI then analyzed using flow cytometry, and the quantitative analysis was located in the right. ∗ p ≤ 0.05, ∗∗ p ≤ 0.01, ∗∗∗ p ≤ 0.001. (e) Levels of p-p53 in A2780/DDP cells were measured by immunofluorescence staining (400x magnification). The panel under the staining shows the quantitative analysis of p-p53 in A2780/CDDP cells. The nuclei are stained with DAPI. ∗ p ≤ 0.05 vs. blank; # p ≤ 0.05 vs. cisplatin. (f) Representative images of the wound healing assays in A2780/CDDP and SKOV3/CDDP cells are shown, and the panels under the images show the wound closure rate. ∗ p ≤ 0.05 vs. 0 h; # p ≤ 0.05 vs. blank; ns means no significance vs. 0 h. (g) The transwell assay was used to analyze the invasion of A2780 and A2780/CDDP cells. The invasive cell number was quantified using ImageJ and located under the images. ∗ p ≤ 0.05. Three independent experiments were performed with similar results. Data are shown as the mean ± SEM.

Article Snippet: The human ovarian cancer cell line A2780 (RRID: CVCL_0134) was purchased from Shanghai Pituo Biological Technology Co., Ltd. (China), and the cell line SKOV3 (RRID: CVCL_0532) was purchased from Solarbio Science & Technology Co., Ltd. (China).

Techniques: Infection, Luciferase, Software, Staining, Flow Cytometry, Immunofluorescence, Transwell Assay

Journal: Oxidative Medicine and Cellular Longevity

Article Title: HSP90AB1 as the Druggable Target of Maggot Extract Reverses Cisplatin Resistance in Ovarian Cancer

doi: 10.1155/2023/9335440

Figure Lengend Snippet: Enrichment analysis of DEGs in A2780/CDDP cells based on high-throughput RNA sequencing. The total RNA from A2780 and A2780/DDP cells was extracted using RNA Miniprep kit reagents. Next-generation sequencing analysis was performed on the BGISEQ-500 platform by BGI Genomic Services. (a) Volcano plot showing significantly upregulated genes (red dots) and downregulated genes (blue dots). (b) A2780 vs. A2780/CDDP Gene Ontology (GO) analysis on a cellular component of DEGs. (c) A2780 vs. A2780/CDDP KEGG pathway enrichment analysis of DEGs. (d) The heat map shows the relative transcript levels of the DEGs in A2780 and A2780/CDDP cells. (e) The protein–protein interaction network shows the upregulated DEGs from A2780/CDDP cells compared with A2780 cells. (f) qRT-PCR analyses of the mRNA levels of MYC in A2780 cells and A2780/CDDP cells. (g) qRT-PCR analyses of the mRNA levels of HSP90AB1 in A2780 cells and A2780/CDDP cells. Three independent experiments were performed with similar results. Data are shown as the mean ± SEM. ∗ p ≤ 0.05, ∗∗∗ p ≤ 0.001.

Article Snippet: The human ovarian cancer cell line A2780 (RRID: CVCL_0134) was purchased from Shanghai Pituo Biological Technology Co., Ltd. (China), and the cell line SKOV3 (RRID: CVCL_0532) was purchased from Solarbio Science & Technology Co., Ltd. (China).

Techniques: High Throughput Screening Assay, RNA Sequencing, Next-Generation Sequencing, Quantitative RT-PCR

Journal: Oxidative Medicine and Cellular Longevity

Article Title: HSP90AB1 as the Druggable Target of Maggot Extract Reverses Cisplatin Resistance in Ovarian Cancer

doi: 10.1155/2023/9335440

Figure Lengend Snippet: ME induces cisplatin to promote apoptosis by suppressing the expression of HSP90AB1/IGF1R in cisplatin-resistant ovarian cancer cells. (a) The expression of HSP90AB1, IGF1R, and IGFBP2 in A2780 cells and A2780/CDDP cells was assessed by western blot. (b) The lower panel shows the quantitative analysis. ∗∗ p ≤ 0.01, ∗∗∗ p ≤ 0.001. (c) The expression of HSP90AB1, IGF1R, and IGFBP2 in SKOV3 cells and SKOV3/CDDP cells was assessed by western blot. (d) The lower panel shows the quantitative analysis. ∗ p ≤ 0.05, ∗∗ p ≤ 0.01. The GSH level in A2780 cells (e) and SKOV3 cells (f) was analyzed using a reduced GSH assay kit. ∗ p ≤ 0.05, ns means no significance. Relative mRNA expression of MYC (g), HSP90AB1 (h), and IGF1R (i) in A2780/CDDP cells was determined by real-time PCR. ∗ p ≤ 0.05, ∗∗∗ p ≤ 0.001, ns means no significance. A2780/CDDP and SKOV3/CDDP cells were treated with cisplatin (3.2 μ g/ml) and ME (6 mg/ml) for 48 h. The protein was extracted for further analysis. (j–m) The protein expression of HSP90AB1, IGF1R, MYC, PTEN, p-H2AX, and BCL2 in A2780/CDDP cells (j) and SKOV3/CDDP cells (l) was measured by western blot. The lower panel shows the quantitative analysis of the western blot in A2780/CDDP cells (K) and SKOV3/CDDP cells (m). ∗ p ≤ 0.05, ns means no significance. Drug-resistant cells were treated with cisplatin, ME, or both. The amount of GSH in A2780/CDDP cells (n) and SKOV3/CDDP cells (o) was analyzed using a reduced GSH assay kit. ∗ p ≤ 0.05, ns means no significance. Three independent experiments were performed with similar results. Data are shown as the mean ± SEM.

Article Snippet: The human ovarian cancer cell line A2780 (RRID: CVCL_0134) was purchased from Shanghai Pituo Biological Technology Co., Ltd. (China), and the cell line SKOV3 (RRID: CVCL_0532) was purchased from Solarbio Science & Technology Co., Ltd. (China).

Techniques: Expressing, Western Blot, GSH Assay, Real-time Polymerase Chain Reaction

Journal: Oxidative Medicine and Cellular Longevity

Article Title: HSP90AB1 as the Druggable Target of Maggot Extract Reverses Cisplatin Resistance in Ovarian Cancer

doi: 10.1155/2023/9335440

Figure Lengend Snippet: Inhibition of HSP90 ATPase activity with geldanamycin promotes apoptosis and suppresses migration in cisplatin-resistant ovarian cancer cells. A2780/CDDP cells and SKOV3/CDDP cells were pretreated with 5 μ M geldanamycin (In-HSP) for 1 h and then treated with cisplatin (3.2 μ g/ml) and ME (6 mg/ml) for 72 h. (a) A2780/CDDP cells and SKOV3/CDDP cells were double stained with Annexin V-FITC and PI and then analyzed by flow cytometry, and the quantitative analysis was located on the right. ∗ p ≤ 0.05, ∗∗ p ≤ 0.01, ∗∗∗ p ≤ 0.001. (b, c) A2780/CDDP cells and SKOV3/CDDP cells expressing luciferase were pretreated with 150 μ g/ml D-luciferin for 10 min. The luciferase-positive A2780/CDDP cells (b) and SKOV3/CDDP cells (c) were analyzed using Living Image software and a GloMax® 96 Microplate Luminometer. The quantification of luciferase-positive cells is shown on the right. ∗∗∗ p ≤ 0.001, ∗∗∗∗ p ≤ 0.0001. Representative images of the wound healing assays of A2780/CDDP cells (d) and SKOV3/CDDP cells (e) are shown, and the quantification of the wound closure rate is on the right. ∗ p ≤ 0.05 vs. 0 h; ns mean no significance vs. 0 h; ## p ≤ 0.01. (f) The expression of HSP90AB1, IGF1R, p-H2AX, p-p53, and BAX in A2780/CDDP cells was analyzed by western blot. (g) The panel on the right shows the quantitative analysis. ∗ p ≤ 0.05. (h) The expression of HSP90AB1, IGF1R, p-H2AX, p-p53, and BCL2 in SKOV3/CDDP cells was measured by western blot. (i) The panel on the right shows the quantitative analysis. ∗ p ≤ 0.05. (j–m) The coimmunoprecipitation assay. SKOV3/CDDP cells were treated with geldanamycin for 24 h. The expression levels of HSP90AB1 and IGF1R were measured (j), and the panel on the right shows the quantitative analysis (k). ∗ p ≤ 0.05. The same cell lysates were immunoprecipitated with IGF1R, HSP90AB1, and isoform-matched immunoglobulin (IgG). (l) Western blot assays of SKOV3/CDDP cells using site-specific antibodies against HSP90AB1 and IGF1R, and the panel on the right shows the quantitative analysis (m). ∗ p ≤ 0.05. Three independent experiments were performed with similar results. Data are shown as the mean ± SEM.

Article Snippet: The human ovarian cancer cell line A2780 (RRID: CVCL_0134) was purchased from Shanghai Pituo Biological Technology Co., Ltd. (China), and the cell line SKOV3 (RRID: CVCL_0532) was purchased from Solarbio Science & Technology Co., Ltd. (China).

Techniques: Inhibition, Activity Assay, Migration, Staining, Flow Cytometry, Expressing, Luciferase, Software, Western Blot, Co-Immunoprecipitation Assay, Immunoprecipitation

Journal: International Journal of Nanomedicine

Article Title: Low-intensity focused ultrasound (LIFU)-induced acoustic droplet vaporization in phase-transition perfluoropentane nanodroplets modified by folate for ultrasound molecular imaging

doi: 10.2147/IJN.S122667

Figure Lengend Snippet: In vitro FA-NDs targeting efficiency. Notes: CLSM images of SKOV3 cells after incubation with FA-NDs or non-NDs. In comparison, SKOV3 cells were first incubated with excess free FA and then FA-ND nanoemulsions under the same conditions (scale bar: 50 μm). Blue, DAPI-stained nuclei; green, DiO-labeled plasmalemma; red, DiI-labeled nanodroplets. Abbreviations: FA-ND, folate-targeted perfluoropentane nanodroplet; CLSM, confocal laser scanning microscopy; DAPI, 4′,6-diamidino-2-phenylindole; DiO, 3,3′-dioctadecyloxacarbocyanine perchlorate; DiI, 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate.

Article Snippet: The SKOV3 human ovarian cancer cell line, which was obtained from Chongqing Key Laboratory of Ultrasound Molecular Imaging (Chongqing, People’s Republic of China), was selected for this research because it overexpresses the FR.

Techniques: In Vitro, Incubation, Comparison, Staining, Labeling, Confocal Laser Scanning Microscopy